They wouldn’t be getting WEHI involved if it wasn’t already known to be useful and safe.
Why test a compound on COVID if it’s not going to be eventually used on humans?
It’s saying to the market, in not-so-many words, that:
-we already know it’s safe in humans,
-we know it enters human cells and inhibits the mTOR pathway,
-we know that blocking the mTOR pathway has been shown to be important in stopping MERS intracellular replication...
MERS, like SARS, is extraordinarily closely related to the virus causing COVID-19, so...
Having WEHI on-board is huge. It’s a world-reknown research institution. Fellows travel from around the world to participate in their research.
The human market is where the serious money is. In our mind, dogs were supposed to pay for the human trials.
Ann: PharmAust to Evaluate Monepantel on COVID-19, page-26
-
- There are more pages in this discussion • 290 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $99.71M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $66.86K | 327.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27750 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 84999 | 3 |
View Market Depth
| Last trade - 14.42pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |